Fyisser pharmaceutical company He stopped creating a daily pill against obesity, which delayed efforts to find new ways to treat obesity from time to time. The company contacted that the drug would stop studying Test, Tanuklipran, a participant in a medical examination Will experience liver failure The person was triggered by the end of the treatment when the person stopped the treatment.
Edition Daily shot of the tablet It was in the initial test phaseResearchers have tried to determine the best level of patients, a spokesman said. The company wanted to send the drug to the final stage of the last and most expensive tests usually before a current company You are possible new treatment To regulatory authorities for approval.
In a statement in a statement of the company, Faizer plans to create and other Treatments against obesity In previous test phases. Obesity Treatments have become one of the most promising and profitable sectors of pharmaceuticals for pharmaceuticals. Copper, de லி lilyFor example, it entered nearly $ 5,000 million (4.6 billion euros) on sale in 2024, which is its first full year in the market.
But the main treatmentsLike the Novo Nortisc’s copper and vagovi, they are injections. Manufacturers are eager to create an easy pill version for patients who do not want to deal with daily needles and injections.
Expensive treatments
Lily researchers believe that they will receive data from a pair of studies Potential oral treatments It has evolved. Although these drugs have become a sales success, many patients have difficulty getting them, due to the recent deficiency or Insurance unequal protection.
Both lily and New Han have announced Recently priced cutsBut treatments may continue to spend hundreds of euros per month, which does not reach some people without security.
Fyser In the late 2023, he contacted that he would leave Danuklipran’s version twice a day, and he advanced to the intermediate test phase after he stopped taking it more than half of a medical examination. A company’s spokesman said the decision This means that Faizer will stop trying Danuklipran in conjunction with other drugs to treat obesity.
